What is Niemann-Pick Disease Market?
Niemann-pick disease is a rare, inherited disease that affects the body's ability to metabolize fat (cholesterol and lipids) within cells. It has an abnormal lipid metabolism that causes a buildup of harmful amounts of lipids in various organs. Its signs and symptoms may involve clumsiness and difficulty walking, excessive muscle contractions or eye movements, sleep disturbances, difficulty swallowing and eating, recurrent pneumonia and others. The factors such as Increased Number of Diagnostic Centres and Increasing Prevalence of Niemann-Pick Disease are driving the global Niemann-Pick Disease market.
The market study is being classified by Type (Niemann-Pick Type A, Niemann-Pick Type B and Niemann-Pick Type C) and major geographies with country level break-up.
Sanofi Genzyme (United States), Aldagen Inc. (United States), Alexion Pharmaceuticals Inc. (United States), CTD Holdings, Inc. (United States), Orphazyme ApS (Denmark), Actelion Pharmaceuticals Ltd (Switzerland), Vtesse Inc. (United States), Merck & Co., Inc. (United States) and Okklo Life Sciences BV (Netherlands) are some of the key players profiled in the study.
The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Niemann-Pick Disease market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Niemann-Pick Disease market by Type, Application and Region.
On the basis of geography, the market of Niemann-Pick Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Number of Diagnostic Centres
- Increasing Prevalence of Niemann-Pick Disease
- Increasing Awareness among People about Healthy LIfestyle
- Non-Avaialability of Total Cure for Niemann-Pick Disease
- Growth in the Healthcare Industry Worldwide
- Technological Advancement in Medical Science
- Stringent Government Rules and Regulations
In September 2019, CTD Holdings, Inc., a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with an unmet medical need, today announced that the company will provide Trappsol Cyclo, its proprietary hydroxypropyl beta-cyclodextrin drug, to a pediatric patient diagnosed with Niemann-Pick Disease Type C.
Key Target AudienceNiemann-Pick Disease Treatment Providers, Distributors, Emerging Companies, Research Professionals and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase